Accelerate Diagnostics Announces Completion Of Its WAVE Pre-Clinical Trial Designed To Deliver Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Culture Bottles And Bacterial Isolated Colonies To Report Accurate Results Within 4.5 Hours, On Average

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average.

It is estimated by the World Health Organization, Sepsis affects an estimated 49 million1 people globally each year, causing an estimated 11 million1 deaths of which an estimated 1.32 million are attributed to bacterial antimicrobial resistance. Additionally, Sepsis is the number one cost to the US healthcare system with an annual estimated expense of $62 billion3. By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance.